Trial Profile
A Randomized, Double-Blind, Chronic Dosing (7-Day), Four-Period, Four-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 24 Aug 2017 New trial record